Bafna Pharmaceuticals Limited reported strong Q1 FY2026 results with a net profit of ₹338.89 lakhs, compared to a loss in the previous year. Revenue from operations increased by 4.02% to ₹3,462.40 lakhs. The company announced its 30th AGM for September 19, 2025, and approved re-appointments of two Independent Directors and the CEO. The Nomination and Remuneration Committee was reconstituted. Bafna Pharmaceuticals also achieved the prescribed Minimum Public Shareholding and completed the sale of assets from its Madhavaram manufacturing unit.